On November 3, 2023 Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, reported the presentation of a poster that provides further positive translational data from the previously completed AWARE-1 breast cancer window-of-opportunity study, sponsored by SOLTI-Innovative Cancer Research, at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 38th Annual Meeting (Press release, Oncolytics Biotech, NOV 3, 2023, View Source [SID1234636889]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Using the novel IMC technology to conduct further translational data analysis from the AWARE-1 study in early-stage breast cancer patients has confirmed and expanded our understanding of pelareorep’s mechanism of action in the tumor microenvironment," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics. "We look forward to incorporating these important translational learnings into our registrational program for HR+/HER2- metastatic breast cancer. These findings likely also have implications for other indications where we have seen signals of efficacy with atezolizumab/pelareorep combinations, including pancreatic cancer in the GOBLET study focused on gastrointestinal cancers."

Thomas Heineman, M.D., Ph.D., Chief Medical Officer at Oncolytics, commented, "Previously published analyses from AWARE-1 patient samples showed that in the first three days after dosing, pelareorep upregulated tumor PD-L1 expression in the tumors, induced the generation and expansion of T cell clones, and promoted the tumor infiltration of CD8+ T cells. It also led to an increase in the CelTIL score in most patients, which is a measure of tumor cellularity and immune infiltration that is associated with favorable clinical outcomes. The new IMC data presented today show an increase in cytotoxic T cells and PD-L1 expression in tumors by three days following treatment and demonstrate pela’s ability to induce an enhanced immune state within tumors. This supports pelareorep’s ability to modify the tumor microenvironment and enhance the responsiveness of cancers to checkpoint inhibitor therapy."

Summary of Data and Findings for Expanded Translational Analysis of the AWARE-1 Study:

Samples: From the AWARE-1 window-of-opportunity study of patients with early-stage HR+/HER2- breast cancer:
•Collected from cohort 2 patients who received pelareorep plus letrozole and atezolizumab (n=10)
•Tumor biopsies were collected on Day 1 (pretreatment), Day 3 (prior to atezolizumab) and Day 21 (when tumors were surgically removed)

Evaluation process:
•Samples were evaluated using a biomarker panel of 37 conjugated antibodies that bind to tumor antigens and immune cells
•The novel IMC technology was used to visualize cellular interactions down to the single cell level

Results: Visualization of the data shows that pelareorep treatment changed the number of PD-L1 tumor cells and the architecture of the tumor microenvironment:
•By Day 3, an increase in PD-L1 positivity and cytotoxic T cells could be seen at a higher rate of tumor infiltration relative to baseline.

About AWARE-1

AWARE-1 was an open-label window-of-opportunity study in early-stage breast cancer. The study combined pelareorep, without or with atezolizumab, and the standard of care therapy according to breast cancer subtype. Tumor tissue was collected from patients as part of their initial breast cancer diagnosis, again on day three following initial treatment, and finally at three weeks following treatment, on the day their tumor is surgically resected. Key objectives of the study were to confirm that pelareorep is acting as a novel immunotherapy, to evaluate potential synergy between pelareorep and checkpoint blockade, and to collect biomarker data. The primary endpoint of the translational study was overall CelTIL score (a measurement of cellularity and tumor-infiltrating lymphocytes). Secondary endpoints for the study included safety and tumor and blood-based biomarkers. AWARE-1 met its primary endpoint of overall CelTIL score in 2021 (link to the PR, link to the poster). Additional biomarker data announced in 2022 showed pelareorep’s potential to improve the prognosis of breast cancer patients (link to the PR, link to the poster).

Poster Information
Poster Title Analysis of the HR+/HER2- breast cancer tumor microenvironment following immune priming with pelareorep and atezolizumab using imaging mass cytometry – Results from the AWARE-1 trial
Abstract Number 582
Poster Date & Time November 4, 2023 from 9 a.m. – 8:30 p.m. Pacific Time

A copy of the poster is available on the Oncolytics website and can be found by clicking here.

On November 3, 2023 Onchilles Pharma, a private biotech company developing cancer therapeutics that leverage a novel mechanism of action, reported the presentation of new preclinical data for N17350 at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 38th Annual Meeting being held virtually and at the San Diego Convention Center from November 1-5, 2023 (Press release, Onchilles Pharma, NOV 3, 2023, View Source [SID1234636888]). The data presented show the potential for N17350, a first-in-class biologic therapeutic inspired by the immunobiology of neutrophils, to become a major new treatment modality for a wide range of cancer types.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our lead drug candidate, N17350, shows a unique combination of potent and selective cancer cell killing and immune activation with the potential to eradicate tumors irrespective of their genetic makeup and anatomical origin," said Lev Becker, Ph.D., Scientific Founder and Board Member of Onchilles Pharma. "These new data presented at SITC (Free SITC Whitepaper) reveal the efficacy of N17350 in difficult-to-treat human xenograft models and establishes a correlation between N17350’s efficacy and elevated histone H1 levels, which are upregulated in cancer cells."

New data presented at SITC (Free SITC Whitepaper) 2023 includes evidence of N17350’s ability to regress tumor growth in a human xenograft model of patient-derived ovarian cancer cell lines as well as colon, lung, and prostate cancers. This builds upon previously presented data at AACR (Free AACR Whitepaper) 2023 showing N17350 efficacy in syngeneic colon (CT26) and metastatic breast (4T1) cancer models. To understand histone H1’s role in this novel mechanism of action, Onchilles’ scientists compared histone H1 levels in cancer cells to non-cancer cells. The results showed that histone H1 levels were elevated in cancer cells and correlated with N17350’s efficacy. Additional data demonstrate that N17350 selectively kills a wide range of cancer cells including those isolated from donor tissue of ovarian cancer patients. Taken together, these findings support a potential broad therapeutic window for this innovative cancer cell-killing mechanism.

"The new preclinical data reported further highlights the broad clinical potential of our lead candidate, N17350, for a wide range of cancer types," said Court R. Turner J.D., Co-Founder and Executive Chair of Onchilles Pharma. "We are on track with our preclinical development efforts which will support advancing N17350 to the clinic next year in skin cancers, head and neck cancer, and triple-negative breast cancer, where treatment options are extremely limited."

About N17350 and Its Novel Mechanism of Action
First described in research published in Cell from the lab of Onchilles’ Co-Founder Lev Becker, human neutrophils release catalytically active neutrophil elastase (called ELANE), which selectively and potently kills cancer cells independent of their genetics and anatomical origin, mobilizes adaptive immunity, and avoids resistance mechanisms. The team at Onchilles translated this ground-breaking discovery into a proprietary set of molecules, including N17350, with the potential to treat a wide variety of tumor types with an optimal efficacy and safety profile.

On November 3, 2023 Integral Molecular, a leading biotech company specializing in antibody discovery against undruggable protein targets reported multispecific molecules targeting GPRC5D, BCMA, and CD3 this week during the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) conference in San Diego (Press release, Integral Molecular, NOV 3, 2023, View Source [SID1234636887]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Recent clinical data demonstrate that combination therapy of T cell engaging molecules individually targeting GPRC5D and BCMA on tumor cells offers unprecedented therapeutic benefits in relapsed/refractory multiple myeloma patients. A trispecific antibody that simultaneously engages these molecules while activating T cells is expected to provide comparable and additional benefits as a monotherapy.

Integral Molecular’s oncology drug discovery program has yielded a panel of high affinity bispecific and trispecific molecules targeting GPRC5D, a GPCR target with complex structural biology. The molecules show picomolar cell-killing activity and are highly selective for their targets.

"For decades we have navigated the complexities of molecules like GPRC5D, successfully discovering antibodies against even the most challenging targets," said Joseph Rucker, PhD, VP of R&D at Integral Molecular. "In just a few short months we were able to simultaneously target GPRC5D and BCMA, and we expect to rapidly advance this molecule into preclinical studies."

The company leveraged its MPS antibody discovery platform to discover and engineer antibodies for this program. MPS is unique from other platforms in the use of RNA, DNA, and virus-like particles (VLPs, or Lipoparticles) to present properly folded membrane proteins, and the use of divergent species (chickens) to generate diverse antibody responses.

Dr. Rucker will present the company’s bi- and trispecific GPRC5D antibodies in a poster during the SITC (Free SITC Whitepaper) 2023 conference. GPRC5D and other antibody assets from Integral Molecular are available for licensing.

On November 3, 2023 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") reported that several abstracts, including one oral presentation, have been selected for the 65th ASH (Free ASH Whitepaper) (American Society of Hematology) Annual Meeting and Exposition, taking place December 9-12, 2023 in San Diego, California (Press release, Innate Pharma, NOV 3, 2023, View Source [SID1234636886]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Lacutamab in patients with T-cell Lymphomas

Abstract details from the TELLOMAK Phase 2 Trial in Patients with Advanced Sézary syndrome include:
The oral presentation will highlight the results from Cohort 1, designed to evaluate safety and efficacy of single agent lacutamab in 56 patients with relapsed/refractory Sézary syndrome after at least two prior systemic therapies including mogamulizumab. At the data cut-off of May 1, 2023, with a global confirmed Objective Response Rate (ORR) of 37.5% (n=21; 95% CI 26.0-50.6) including 2 Complete Responses (CRs), confirmed ORR in skin of 46.4% (n=26; 95% CI 34.0-59.3) including 5 CRs and confirmed ORR in blood of 48.2% (n=27; 95% CI 35.7-61.0) including 15 CRs, data confirm that lacutamab monotherapy shows promising clinical activity in a heavily pre-treated relapsed/refractory population previously treated with a median of 6 prior lines (range 2-15), including mogamulizumab, and an overall favorable safety profile. Clinical Benefit Rate (CBR, defined as CR+PR+SD) was 87.5 % (n=49; 95% CI 76.4-93.8). Median PFS was 8.0 months (95% CI 4.7, 21.2). Continued evaluation of this promising new targeted treatment option for patients with Sezary Syndrome is warranted.

Preliminary Monotherapy Clinical Data and Pre-Clinical Combinability Data in Patients with Peripheral T-Cell Lymphoma (PTCL):
The poster will display preclinical combination data supporting anti-tumor activity and rationale for the exploration of lacutamab in combination with approved and novel therapies in patients with PTCL. Preliminary monotherapy data from an ongoing Phase 1b study in PTCL is also presented.

SAR443579/IPH6101 in patients with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL) or high-risk myelodysplasia (HR-MDS) (from a Joint Research Collaboration with Sanofi)

A presentation from the Sanofi oncology pipeline at ASH (Free ASH Whitepaper) includes updated efficacy and safety results from an open-label, first-in-human, dose-escalation study of an investigational CD123 targeting Natural Killer Cell Engager (NKCE). Results investigating SAR443579 as a monotherapy for the treatment of blood cancers with high unmet needs, including relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia and high-risk myelodysplasia show data across all dose levels tested. Observed clinical remissions will also be presented. Abstract details include:

As of July 5, 2023, 43 patients (42 R/R AML and 1 HR-MDS) across 8 Dose Levels (DLs) at 10 – 6000 μg/kg/dose were included. Patients had received a median of 2.0 (1.0 – 10.0) prior lines of treatment with 13 patients (30.2%) reporting prior hematopoiectic stell cell transplantation and 36 patients (83.7%) with prior exposure to venetoclax. In DLs with a highest dose of 1000 μg/kg QW, 5/15 (33.3%) patients achieved a CR (4 CR / 1 CRi) as of the cut-off date. Data from PK/PD and in vitro mechanistic analyses studying dose-response relations will also be presented. SAR443579 was well tolerated up to doses of 6000 μg/kg QW with observed clinical benefit in patients with R/R AML. The results are consistent with the predicted favorable safety profile.

ASH abstract details:

Lacutamab

Oral Presentation

Publication Number: 185
Title: Lacutamab in Patients with Relapsed and Refractory Sézary Syndrome: Results from the Tellomak Phase 2 Trial
Session Name: 624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Topics in T Cell, Sezary and Hodgkin Lymphomas
Session Date and Time: Saturday, December 9, 2023 3:00 PM
Presenter: Prof Porcu
Room: Manchester Grand Hyatt San Diego, Grand Hall B
Poster session

Publication Number: 3072
Title: Strategies to Develop Anti-KIR Mab Lacutamab in Patients with Peripheral T-Cell Lymphoma: Preliminary Monotherapy Clinical Data and Pre-Clinical Combinability Data
Session Name: 624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster II
Session Date: Sunday, December 10, 2023
Presentation Time: 6:00 PM – 8:00 PM
Location: San Diego Convention Center, Halls G-H
SAR443579 / IPH6101 (Sanofi collaboration)

Publication Number: 3474
Title: First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics
Session Name: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II
Session Date: Sunday, December 10, 2023
Presentation Time: 6:00 PM-8:00 PM
Location: San Diego Convention Center, Halls G-H

On November 3, 2023 IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, reported new positive preclinical data from its induced pluripotent stem cell (iPSC) gamma-delta T cell platform at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 38th Annual Meeting (Abstract #: 637 in Exhibit Halls A and B1) (Press release, In8bio, NOV 3, 2023, View Source [SID1234636885]). The data represents a significant advance in the development of the INB-500 iPSC program towards the development of allogeneic gamma-delta T cell therapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our deep understanding of gamma-delta T cell biology allows for significant ex vivo expansion capabilities," said William Ho, Co-founder and CEO. "We have successfully developed and utilized a robust serum and feeder-free process for generating iPSC derived gamma-delta T cells, representing an important step towards developing a truly allogeneic ‘off-the-shelf’ gamma-delta T cell source for therapeutic development."

The presented data underscores the platform’s ability to reprogram donor cells into iPSCs, expand them, and guide their differentiation into gamma-delta T cells through IN8bio’s proprietary process, which can be scaled for full GMP manufacturing. Notably, the platform enables the differentiation into both Vd1+ and Vd2+ cell subtypes using cell-type specific processes. The iPSC-derived gamma-delta T cells underwent comprehensive characterization, encompassing morphological analysis, cell surface markers and functional assessment via tumor cell killing assays. Key findings include:

iVd1+ gamma-delta T cells expressed the cell markers expected of innate gamma-delta T cells, including a strong capacity for cytokine release, indicating that the cells possess an effector phenotype.
To date, hundreds of millions of iVd1+ gamma-delta T cells have been produced from single iPSC clones at a low passage number.
The cells demonstrated robust cytotoxic activity across a variety of cancer cell lines, including ovarian, glioblastoma (GBM), acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) cell lines, potentially providing an allogeneic platform for a broad range of cancers.
Cryopreservation did not impact the cells with the Vd1+ gamma-delta T cells showing comparable cytotoxicity to fresh cells, which allows them to be expanded and banked for potential on-demand clinical use.
"High concentrations of gamma-delta T cells in both peripheral blood and in solid tumor infiltrates are associated with improved survival outcomes in both hematopoietic and solid cancers," said Lawrence Lamb, PhD, Co-founder and Chief Scientific Officer. "iPSC-derived gamma-delta cells could address existing challenges, including donor sourcing and limitations of sufficient cell numbers to sustain a therapeutic effect particularly in solid tumors. iPSCs, with their nearly unlimited self-renewal capacity, multi-lineage differentiation potential, and relative ease of generic engineering offer the possibility of therapeutic cell production for patients across a wide range of cancers."